Compare YHGJ & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YHGJ | APVO |
|---|---|---|
| Founded | 1975 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1M | 8.3M |
| IPO Year | 2006 | 2023 |
| Metric | YHGJ | APVO |
|---|---|---|
| Price | $3.43 | $4.88 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 6.2K | ★ 21.6K |
| Earning Date | 05-19-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 0.13 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $19,705,000.00 | $3,114,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 9.76 | N/A |
| 52 Week Low | $0.47 | $0.50 |
| 52 Week High | $10.29 | $13.11 |
| Indicator | YHGJ | APVO |
|---|---|---|
| Relative Strength Index (RSI) | 60.20 | 50.39 |
| Support Level | $3.40 | $3.88 |
| Resistance Level | $3.50 | $5.66 |
| Average True Range (ATR) | 0.34 | 0.34 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 85.34 | 49.74 |
Yunhong Green CTI Ltd develops, produces, distributes, and sells consumer products in the United States and several other countries, and manufactures film products for commercial and industrial use in the United States. The Company focuses on flexible film technologies and has developed products utilizing flexible films, including novelty balloons, pouches, and films for packaging applications. Its principal product lines include foil and latex balloons and related gift items, and flexible films for food and other packaging uses. It also assembles balloon-inspired gift items, including small gift bouquets with ribbons and/or a foil balloon, and holds patents related to flexible films, including films, zipper closures, valves, and other features.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.